Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $117.00

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given a consensus rating of “Buy” by the twenty-two analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nineteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $117.00.

A number of brokerages have recently commented on KYMR. B. Riley Financial lifted their target price on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Barclays upped their target price on shares of Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a report on Tuesday, January 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. JPMorgan Chase & Co. boosted their price target on Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Finally, Wells Fargo & Company boosted their price objective on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, December 9th.

Insider Transactions at Kymera Therapeutics

In related news, Director Bruce Booth sold 678 shares of Kymera Therapeutics stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $91.04, for a total value of $61,725.12. Following the sale, the director directly owned 685,393 shares in the company, valued at $62,398,178.72. The trade was a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 420,895 shares of company stock valued at $37,778,351 over the last 90 days. Insiders own 16.01% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently made changes to their positions in the stock. Legato Capital Management LLC grew its stake in shares of Kymera Therapeutics by 40.6% during the 4th quarter. Legato Capital Management LLC now owns 9,534 shares of the company’s stock worth $742,000 after purchasing an additional 2,751 shares during the period. Keudell Morrison Wealth Management acquired a new stake in shares of Kymera Therapeutics in the fourth quarter valued at about $514,000. Eagle Health Investments LP purchased a new stake in Kymera Therapeutics during the fourth quarter worth about $10,606,000. PSP Research LLC purchased a new stake in Kymera Therapeutics during the fourth quarter worth about $494,000. Finally, Larson Financial Group LLC grew its position in Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after buying an additional 287 shares during the period.

Kymera Therapeutics Stock Performance

KYMR opened at $79.59 on Monday. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00. The stock has a market capitalization of $5.73 billion, a P/E ratio of -22.17 and a beta of 2.21. The business’s 50-day simple moving average is $76.61 and its 200-day simple moving average is $60.82.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The firm had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. On average, equities research analysts forecast that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.